Company on track to report topline data in first half of 2025 Positive preliminary data from all five single ascending dose (SAD) cohorts ranging from 15mg to 450mg support safety and tolerability of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback